| 001 | 305740 | ||
| 005 | 20251222120254.0 | ||
| 024 | 7 | _ | |a 10.1016/j.radonc.2025.111276 |2 doi |
| 024 | 7 | _ | |a pmid:41213475 |2 pmid |
| 024 | 7 | _ | |a 0167-8140 |2 ISSN |
| 024 | 7 | _ | |a 1879-0887 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2025-02363 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Seiler, Isabell |b 0 |
| 245 | _ | _ | |a Impact of target volume and dose concepts on the outcomes of prostate cancer patients treated with stereotactic body radiotherapy for spinal metastases - a European multicenter cohort study. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2026 |b Elsevier Science |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1766401342_3634864 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a Volume 214, January 2026, 111276 |
| 520 | _ | _ | |a The importance of metastasis-directed radiotherapy is increasing in the management of oligometastatic prostate cancer. We evaluated different target volume and dose concepts for stereotactic body radiotherapy (SBRT) of spine bone metastases (BoM) from prostate cancer in a large European cohort.Data of prostate cancer patients receiving SBRT for spine BoM between 2010 and 2024 at 19 European cancer centers were retrospectively collected. Treatment volumes and dose concepts were analyzed regarding their impact on overall survival (OS), freedom from local recurrence (FFLR), biochemical recurrence-free survival (BRFS), and progression-free survival (PFS).With a median follow-up of 25.1 months (range: 1.4-77.2), 213 patients with 283 spine BoM were evaluated. 1-/3-year PFS with simultaneously integrated boost (SIB) were 85.7 %/73.9 % (BED4 [Biologically effective dose with α/β-ratio = 4 Gy] ≥ 100 Gy) and for non-SIB concepts 81.2 %/45.5 % (BED4 ≥ 100 Gy), respectively. 1-/3-year BRFS for SIB-treated BoM amounted to 81.7 %/68.4 % (BED4 ≥ 100 Gy) and for non-SIB 78.3 %/43.6 % (BED4 ≥ 100 Gy). OS was not significantly different for the evaluated dose and target volume concepts. For FFLR a significant difference was observed favoring BED4 ≥ 100 Gy. In multivariable analysis, following factors were positively associated with both PFS and BRFS: BED4 for GTVmean dose and SIB concept. Adverse events were very low, with fracture rates of 2.2 %.This multicenter cohort analysis showed that SBRT of spine BoM from prostate cancer is an effective and well-tolerated treatment. Both BED and usage of a SIB concept were associated with improved PFS and BRFS. Prospective studies are needed to confirm these findings and further standardize SBRT concepts. |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Bone metastases |2 Other |
| 650 | _ | 7 | |a Dose concept |2 Other |
| 650 | _ | 7 | |a Metastasis-Directed therapy (MDT) |2 Other |
| 650 | _ | 7 | |a Prostate cancer |2 Other |
| 650 | _ | 7 | |a Spine metastases |2 Other |
| 650 | _ | 7 | |a Stereotactic radiotherapy |2 Other |
| 650 | _ | 7 | |a Target concept |2 Other |
| 700 | 1 | _ | |a Schäfer, Sebastian |b 1 |
| 700 | 1 | _ | |a von Wachter, Camilla |b 2 |
| 700 | 1 | _ | |a Balermpas, Panagiotis |b 3 |
| 700 | 1 | _ | |a Slavik, Marek |b 4 |
| 700 | 1 | _ | |a Burkon, Petr |b 5 |
| 700 | 1 | _ | |a Meents, Johannes |b 6 |
| 700 | 1 | _ | |a Kästner, Lena |b 7 |
| 700 | 1 | _ | |a Lohaus, Fabian |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Willner, Jochen |b 9 |
| 700 | 1 | _ | |a Schunn, Anna Sabrina |b 10 |
| 700 | 1 | _ | |a Drabke, Sophia |b 11 |
| 700 | 1 | _ | |a Klischies, Kenneth |b 12 |
| 700 | 1 | _ | |a Wittenstein, Olaf |b 13 |
| 700 | 1 | _ | |a Bank, Priska |b 14 |
| 700 | 1 | _ | |a Partl, Richard |b 15 |
| 700 | 1 | _ | |a Müller, Jörg-Andreas |b 16 |
| 700 | 1 | _ | |a Gawish, Ahmed |b 17 |
| 700 | 1 | _ | |a Grün, Arne |b 18 |
| 700 | 1 | _ | |a Baehr, Andrea |b 19 |
| 700 | 1 | _ | |a Trommer, Maike |b 20 |
| 700 | 1 | _ | |a Glasmacher, Andrea |b 21 |
| 700 | 1 | _ | |a Mader, Thomas |b 22 |
| 700 | 1 | _ | |a Holy, Richard |b 23 |
| 700 | 1 | _ | |a Dzierma, Yvonne |b 24 |
| 700 | 1 | _ | |a Ehret, Felix |0 P:(DE-HGF)0 |b 25 |
| 700 | 1 | _ | |a Rühle, Alexander |b 26 |
| 700 | 1 | _ | |a Guckenberger, Matthias |b 27 |
| 700 | 1 | _ | |a Moustakis, Christos |b 28 |
| 700 | 1 | _ | |a Brunner, Thomas |b 29 |
| 700 | 1 | _ | |a Blanck, Oliver |b 30 |
| 700 | 1 | _ | |a Boda-Heggemann, Judit |b 31 |
| 700 | 1 | _ | |a Nicolay, Nils H |b 32 |
| 700 | 1 | _ | |a Nägler, Franziska |b 33 |
| 773 | _ | _ | |a 10.1016/j.radonc.2025.111276 |g p. 111276 - |0 PERI:(DE-600)1500707-8 |p 111276 |t Radiotherapy and oncology |v 214 |y 2026 |x 0167-8140 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:305740 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 25 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2025-01-07 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-01-07 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-01-07 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-01-07 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2025-01-07 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-01-07 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2025-01-07 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2025-01-07 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-01-07 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-01-07 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b RADIOTHER ONCOL : 2022 |d 2025-01-07 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2025-01-07 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2025-01-07 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b RADIOTHER ONCOL : 2022 |d 2025-01-07 |
| 920 | 1 | _ | |0 I:(DE-He78)DD01-20160331 |k DD01 |l DKTK Koordinierungsstelle Dresden |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)BE01-20160331 |k BE01 |l DKTK Koordinierungsstelle Berlin |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)DD01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)BE01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::